Phase I trial of COTI 2 in patients with recurrent head and neck squamous cell cancer.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs COTI 2 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 25 Jan 2018 According to a Cotinga Pharmaceuticals media release, the company expects to report initial safety data in the second quarter of 2018.
- 25 Jan 2018 Status changed from planning to recruiting, according to a Cotinga Pharmaceuticals media release.
- 22 Jan 2015 New trial record